Fertility services provider Jinxin Fertility Group is looking to raise up to US$600 million in an IPO in Hong Kong.
Founded 20 years ago in Chengdu, Jinxin Fertility was the first medical institution to be licensed by the Ministry of Health to offer human assisted reproductive services in Sichuan Province and the first assisted reproductive centre established in Shenzhen. It is currently the third-largest IVF clinic chain in the country.
Backed by Warburg Pincus and CNCB it owns and manages a number of clinics in Chengdu and Shenzhen in China – Chengdu Xinan Hospital, Shenzhen Zhongshan Hospital, and Jinjiang IVF Center – as well as HRC Medical in the US.
For the nine months to September last year Jinxin Fertility had profits of Rmb174.5 million (US$25.7 million) on revenues of Rmb669.6 million.
Funds raised will mostly be used for expansion of its current facilities as well as acquisitions.
CLSA and Morgan Stanley are managing the deal.